Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Long-Term Protective Efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above

NCT07293065 is registered in ClinicalTrials.gov with MAXVAX Biotechnology Limited Liability Company as lead sponsor.

NCT NCT07293065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07293065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Long-Term Protective Efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above
Lead sponsor
MAXVAX Biotechnology Limited Liability Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 15, 2025
Completion date
December 31, 2028
Enrollment
12,000 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster